Cargando…

Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis

BACKGROUND: Malignancies in the urinary tract and the kidney graft are quite common after kidney transplantation. In some selected cases tumours develop from donor-derived tissue. OBJECTIVES: We hypothesised that there is a clinical value to investigate donor/recipient origin in urologic malignancie...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellström, Vivan, Tufveson, Gunnar, Loskog, Angelica, Bengtsson, Mats, Enblad, Gunilla, Lorant, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491581/
https://www.ncbi.nlm.nih.gov/pubmed/36129920
http://dx.doi.org/10.1371/journal.pone.0271293
_version_ 1784793305927647232
author Hellström, Vivan
Tufveson, Gunnar
Loskog, Angelica
Bengtsson, Mats
Enblad, Gunilla
Lorant, Tomas
author_facet Hellström, Vivan
Tufveson, Gunnar
Loskog, Angelica
Bengtsson, Mats
Enblad, Gunilla
Lorant, Tomas
author_sort Hellström, Vivan
collection PubMed
description BACKGROUND: Malignancies in the urinary tract and the kidney graft are quite common after kidney transplantation. In some selected cases tumours develop from donor-derived tissue. OBJECTIVES: We hypothesised that there is a clinical value to investigate donor/recipient origin in urologic malignancies in renal transplant recipients. METHODS: In this retrospective study, including patients transplanted between the years 1969 and 2014 at Uppsala University Hospital, Sweden, 11 patients with malignancies in urinary tract and 4 patients with malignancies in kidney transplants were investigated. Donor/recipient origin of tumour tissue was analysed by polymerase chain reaction (PCR) of human leucocyte antigen (HLA) genotypes or by fluorescence in situ hybridization (FISH analysis) of sex chromosomes. HLA genotype and sex chromosomes of the tumour were compared to the known HLA genotype and sex chromosomes of recipient and donor. RESULTS: Three of ten cancers in the urinary tract and three of four cancers in the kidney transplants were donor-derived. CONCLUSIONS: We suggest that urologic malignancies in renal transplant recipients can be investigated for transplant origin. In addition to conventional therapy the allograft immune response against these tumours can be valuable to treat donor-derived cancers.
format Online
Article
Text
id pubmed-9491581
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94915812022-09-22 Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis Hellström, Vivan Tufveson, Gunnar Loskog, Angelica Bengtsson, Mats Enblad, Gunilla Lorant, Tomas PLoS One Research Article BACKGROUND: Malignancies in the urinary tract and the kidney graft are quite common after kidney transplantation. In some selected cases tumours develop from donor-derived tissue. OBJECTIVES: We hypothesised that there is a clinical value to investigate donor/recipient origin in urologic malignancies in renal transplant recipients. METHODS: In this retrospective study, including patients transplanted between the years 1969 and 2014 at Uppsala University Hospital, Sweden, 11 patients with malignancies in urinary tract and 4 patients with malignancies in kidney transplants were investigated. Donor/recipient origin of tumour tissue was analysed by polymerase chain reaction (PCR) of human leucocyte antigen (HLA) genotypes or by fluorescence in situ hybridization (FISH analysis) of sex chromosomes. HLA genotype and sex chromosomes of the tumour were compared to the known HLA genotype and sex chromosomes of recipient and donor. RESULTS: Three of ten cancers in the urinary tract and three of four cancers in the kidney transplants were donor-derived. CONCLUSIONS: We suggest that urologic malignancies in renal transplant recipients can be investigated for transplant origin. In addition to conventional therapy the allograft immune response against these tumours can be valuable to treat donor-derived cancers. Public Library of Science 2022-09-21 /pmc/articles/PMC9491581/ /pubmed/36129920 http://dx.doi.org/10.1371/journal.pone.0271293 Text en © 2022 Hellström et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hellström, Vivan
Tufveson, Gunnar
Loskog, Angelica
Bengtsson, Mats
Enblad, Gunilla
Lorant, Tomas
Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
title Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
title_full Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
title_fullStr Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
title_full_unstemmed Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
title_short Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
title_sort donor-derived urologic cancers after renal transplantation: a retrospective non-randomized scientific analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491581/
https://www.ncbi.nlm.nih.gov/pubmed/36129920
http://dx.doi.org/10.1371/journal.pone.0271293
work_keys_str_mv AT hellstromvivan donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis
AT tufvesongunnar donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis
AT loskogangelica donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis
AT bengtssonmats donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis
AT enbladgunilla donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis
AT loranttomas donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis